Alzheimer's disease Trials in Sunrise, United States
Conditions / Alzheimer's disease / Sunrise, United States
Research into Alzheimer's disease spans multiple therapeutic approaches and trial phases.
27 total trials for this combination
Showing top 10 of 27 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT01900665 | Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo | TERMINATED | PHASE3 |
| NCT02004392 | Study of the Safety and Clinical Effects of 2 Doses of EVP-6124 in Subjects With Alzheimer's Disease Who Complete Study EVP-6124-024 or EVP-6124-025 | TERMINATED | PHASE3 |
| NCT01767311 | A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease | COMPLETED | PHASE2 |
| NCT01969136 | Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease | TERMINATED | PHASE3 |
| NCT00627029 | Evaluation of Programs of Coordinated Care and Disease Management | UNKNOWN | NA |
| NCT02079246 | Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease | COMPLETED | PHASE3 |
| NCT00594568 | Effect of LY450139 on the Long Term Progression of Alzheimer's Disease | COMPLETED | PHASE3 |
| NCT02245737 | An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease | TERMINATED | PHASE2/PHASE3 |
| NCT00380276 | Open-Label Treatment With MPC-7869 for Patients With Alzheimer's Who Previously Participated in an MPC-7869 Protocol | TERMINATED | PHASE3 |
| NCT01127633 | Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease | TERMINATED | PHASE3 |